Ariad names Jennifer Herron as chief commercial officer

25 May 2016

US drugmaker Ariad Pharmaceuticals (Nasdaq: ARIA) has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016.

She will report to Ariad’s president and chief executive officer, Paris Panayiotopoulos, who took over this position just at the start of this year (The Pharma Letter December 21, 2015. Ms Herron will succeed Martin Duvall, who has made significant contributions to Ariad since first joining the company in 2011. Mr Duvall will work closely with Ms Herron to ensure a seamless transition.

”I am delighted that Jennifer will be joining Ariad as our chief commercial officer,” stated Mr Panayiotopoulos, adding: “Jennifer is a proven leader with over 23 years of pharmaceutical experience across multiple therapeutic areas, specifically oncology, immunoscience and cardio-vascular/metabolics, which I am confident will serve her well in maximizing the commercial opportunity for Iclusig [ponatinib]and, if approved, brigatinib.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK